Form 4: Exagen Inc. President and CEO John Aballi Acquires Shares and Stock Options

John Aballi, President and CEO of Exagen Inc., reports the acquisition of restricted stock units and stock options, signaling changes in his beneficial ownership of the company's securities.

Summary

• On February 21, 2025, John Aballi, the President and CEO of Exagen Inc., acquired 112,500 shares of common stock in the form of restricted stock units and stock options.
• He also acquired options to purchase 75,000 shares of common stock at an exercise price of $3.58.
• The restricted stock units vest 25% annually over four years, contingent upon continued service, and may fully vest upon a qualifying termination of employment in connection with a change in control.
• The stock options vest 25% on February 21, 2026, and then 1/48th monthly thereafter, also subject to continued service, with potential for full vesting upon a change in control.
• Following these transactions, Aballi directly owns 737,593 shares of common stock and indirectly owns 40,401 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by the CEO suggests confidence, but it's a routine filing and doesn't provide strong positive or negative signals.

Positives

• The acquisition of shares and options by the CEO could be interpreted as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the restricted stock units and stock options incentivize continued service and commitment from the CEO.

Risks

• The vesting of the restricted stock units and stock options is contingent upon continued service, creating a potential risk if the CEO were to leave the company before the vesting dates.
• A change in control could trigger full vesting, potentially diluting existing shareholders' equity.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest a multi-year commitment from the CEO.

Industry Context

This type of filing is standard for corporate insiders and reflects compensation practices common in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies to incentivize executives.
• Vesting schedules, like the four-year vesting described in the document, are standard in the industry to ensure long-term commitment.
• The specific terms of the equity awards (number of shares, exercise price, vesting schedule) would need to be compared to peer companies in the diagnostics or biotechnology sector to assess their competitiveness.

Stakeholder Impact

• Shareholders may view the CEO's increased stake in the company positively.
• Employees may be motivated by the CEO's commitment and alignment with the company's long-term success.

Key Dates